Fundraising Fox
Cure51
Founded 2021 · 61 employees on LinkedIn · 4 known investors
Find your way into Cure51
Sign up to find every way you can get introduced to Cure51
- Your email: who you already know at Cure51, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Cure51 team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Cure51 is a cancer research company that decodes the biology of exceptional cancer survivors ("cancer outliers") using molecular profiling and computational biology, collecting patient data on its Patient Profile Platform. It works with cancer centers and clinical partners as part of the Rosalind Study to advance cancer research.
Founders & leadership
Cure51 was founded in 2021 by Paloma Cejas and Rémy Nicolle.
Investors · 4
How we know: funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Kima Ventures's portfolio page · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountseed roundMar 2024 · 4 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Cure51 do?
- Cure51 is a cancer research company that decodes the biology of exceptional cancer survivors ("cancer outliers") using molecular profiling and computational biology, collecting patient data on its Patient Profile Platform. It works with cancer centers and clinical partners as part of the Rosalind Study to advance cancer research.
- Who founded Cure51?
- Cure51 was founded by Paloma Cejas, Rémy Nicolle in 2021.
- Who are Cure51's investors?
- Cure51's investors include Hitachi Ventures, Kima Ventures, LifeX Ventures, Sofinnova Partners.